Introduction {#Sec1}
============

Non-small cell lung cancer (NSCLC, representing approx. 85 % of lung cancer cases) is still the most common cause of death (1.6 million in 2012) due to malignancies in developed countries \[[@CR1]\]. Despite the dynamic development of medicine, the chemotherapy based on platinum compounds (cis- or carboplatin) and third generation drugs (e.g. gemcitabine) still remains standard regimen of the first-line treatment of advanced NSCLC. After administration of standard first-line chemotherapy, the objective response rates (ORR) varies between 20 and 30 %. Chemotherapy provides slight prolongation of patients' survival time (1.5 months compared to the best supportive care, BSC); however, its use is associated with occurrence of relevant toxicity. Median overall survival (OS) of patients treated by systemic therapy range from 6 to 12 months \[[@CR2]\]. Identification of driver mutations or other gene alterations (e.g. activating mutations in the *EGFR* and *ALK* rearrangements), which are potential molecular targets, seems to be an important advancement in optimization and individualization of NSCLC therapy. These drugs significantly improved treatment outcomes (over 60 % ORR, progression free survival (PFS) prolonged to 10 months) with acceptable toxicity \[[@CR3]--[@CR6]\]. Only 10--30 % (*EGFR* mutations) or 3--7 % (*ALK* rearrangements) Caucasian patients with advanced non-squamous NSCLC have molecular alterations and should be treated by target therapy. The lack of identified molecular targets for squamous cell carcinoma treatment is the reason why majority of patients still receive standard chemotherapy \[[@CR7]--[@CR9]\]. On the other hand, genetic predisposition (e.g. gene polymorphisms or mRNA expression) may be used to selection for potentially the most effective treatment regimens, which can prolong the life of patients and improve its quality \[[@CR10]--[@CR12]\]. Among the molecular changes, potentially the highest impact on the efficacy of chemotherapy have alterations of genes, which coding proteins involved in drug metabolism. Gemcitabine is frequently used in the treatment of NSCLC, ovarian and pancreatic cancer. Its mechanism of action is based on the incorporation to nucleic acids, which consequently induce apoptosis. The excess of deoxycytidine, biosynthesized with the participation of RRM1 causes competitive displacement of gemcitabine, reducing the efficacy of this chemotherapeutic agent \[[@CR13], [@CR14]\]. Some researchers have demonstrated that in patients with NSCLC the expression or SNPs of *RRM1* may play prognostic and predictive role (e.g. for gemcitabine). The influence of single nucleotide polymorphisms (SNPs) on survival and the response to treatment with platinum compounds and gemcitabine in patients with advanced NSCLC are still not fully understood. Among the already known *RRM1* SNPs, −37C\>A (rs12806698) and −524C\>T (rs11030918) seem to have the greatest importance as potential predictors of treatment regimens based on gemcitabine in NSCLC patients \[[@CR15]--[@CR17]\].

The aim of this study was to determine the association between SNPs of *RRM1* promoter (−37C\>A, −524C\>T) and the effectiveness of chemotherapy based on platinum compounds and gemcitabine in patients with inoperable or advanced NSCLC.

Materials and methods {#Sec2}
=====================

The study was performed on 91 Caucasian patients with inoperable, locally advanced or metastatic NSCLC (IIIB and IV), treated from 2010 to 2013 at the Department of Pneumonology, Oncology and Allergology, Medical University of Lublin. NSCLC diagnosis was based on histopathological or cytological examination. In the first-line treatment all patients received standard chemotherapy, based on platinum compounds and gemcitabine. The stage of disease was evaluated according to the TNM classification (VII edition by UICC). The median number of cycles of first-line chemotherapy was 4 (range 2--6). Subsequent lines of therapy: second or third were used in 56.1 and 16.5 % of patients, respectively (Table [1](#Tab1){ref-type="table"}). Response to treatment was evaluated by RECIST V1.1 (Response Evaluation Criteria in Solid Tumors). Adverse events were estimated by Common Toxicity Criteria for Adverse Events (CTCAE) V4.0.Table 1Patient characteristicsVariableStudy group (*n* = 91)Sex Male61 (67 %) Female30 (33 %)Age (years) Median62 Mean ± SD62.5 ± 7.9 Range38--78Smoking status (pack-years) Median30 Mean ± SD31.4 ± 9.5 Non-smokers5 (5.5 %) Current smokers65 (71.4 %) Former Smokers20 (22 %) No data1 (1.1 %)Histopathological diagnosis Adenocarcinoma46 (50.5 %) Squamous cell carcinoma14 (15.4 %) Large cell carcinoma16 (17.6 %) NOS (not otherwise specified)15 (16.5 %)Stage of disease IIIB28 (30.8 %)  IV63 (69.2 %)Performance status PS = 012 (13.2 %) PS ≥ 179 (86.8 %)Weight loss before CTH Yes39 (42.9 %) No43 (47.2 %) No data9 (9.9 %)Anemia before CTH Yes59 (64.8 %) No32 (35.2 %)Side effect after I line CTH Yes59 (64.8 %) No24 (26.4 %) No data8 (8.8 %)Subsequent lines of treatment Yes51 (56.1 %) No40 (43.9 %)Second-line CTH (monotherapy)**51 (56.1** **%)** ERL12 (13.2 %) PEM26 (28.6 %) DCX13 (14.3 %)Third-line CTH (monotherapy)**15 (16.5** **%)** ERL5 (5.5 %) PEM6 (6.6 %) DCX4 (4.4 %)*ERL* erlotinib, *DCX* docetaxel, *PEM* pemetrexed

The isolation of DNA from peripheral blood leukocytes was performed using DNA Blood Mini Kit (Qiagen, Canada). Quality and quantity of extracted DNA were measured using a spectrophotometer BioPhotometer plus in cuvette equipped with UV/VIS filters (Eppendorf, Germany). Analysis of SNPs was conducted using the mini-sequencing technique (SNaPshot^®^ PCR). For the reaction, a set of ABI PRISM SNaPshot^®^ Multiplex (Life Technologies, USA) was used. An example of the results of genotyping is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Example of genotyping results of *RRM1* gene obtained by capillary electrophoresis of the SNaPshot PCR products. From *left* (−37C\>A and −524C\>T respectively): AC and TT heterozygotes, CC and TT homozygotes

Statistical analysis {#Sec3}
--------------------

Statistical analysis was done using Statistica 10 (Statsoft, USA) and MedCalc 10 (MedCalc Software, Belgium). The results of *p* \< 0.05 were considered to be statistically significant. Using the Chi-Square (*χ*^2^) balance of the Hardy--Weinberg (HW) equilibrium, associations between a series factors with the distribution of *RRM1* polymorphisms were calculated. The Kaplan--Meier method was used to draw a comparison curve evaluating the survival probability (PFS and OS). Cox regression model with a stepwise selection with minimum AIC factor (Akaike Information Criterion) was used to determine the influence of clinical and genetic factors on survival. The median survival in the groups was compared by the use of the *U*-Mann--Whitney test.

Results {#Sec4}
=======

Distributions of genotypes in the *RRM1* (−37C\>A, −524C\>T) did not depend on factors such as gender, age, histological type, stage of disease, performance status or smoking status (Table [2](#Tab2){ref-type="table"}). The distribution of genotypes within the SNP −524C\>T, unlike the −37C\>A, was in Hardy--Weinberg equilibrium (*p* = 0.0966, *χ*^2^ = 2.7612 for −524C \> T and *p* = 0.0279, *χ*^2^ = 4.8336 for −37C\>A). Genotypes AA, AC and CC of *RRM1* (−37C\>A) occurred respectively in 5.7, 54.5 and 39.8 % of patients. Genotypes CC, CT and TT of *RRM1* (−524C\>T) occurred, respectively, in 7.7, 52.7 and 39.6 % of patients. Due to the fact that studied SNPs are located in the same gene (on chromosome 11) using the online tool SNAP (Broad Institute, USA) and data from the International HapMap project assesses coupling allele linkage disequilibrium (LD), LD was calculated based on data from population-based genetic studies (Utah state residents whose ancestors came from the north-western regions of Europe--CEU). Analyzed pair of SNPs has not reached the correlation coefficient *R*^2^ \> 0.8 so, we concluded that they do not create haplotypes and are not subject to the common inheritance.Table 2*RRM1* gene genotypes distribution according to demographic and clinical factorsVariable*RRM1* (−37C\>A)*p*, *χ* ^2^*RRM1* (−524C\>T)*p*, *χ* ^2^AAACCCCCCTTT5 (5.7 %)48 (54.5 %)35 (39.8 %)7 (7.7 %)48 (52.7 %)36 (39.6 %)Sex Male2 (6.7 %)16 (53.3 %)12 (40 %)0.95573 (10 %)14 (46.7 %)13 (43.3 %)0.6755 Female3 (5.2 %)32 (55.2 %)23 (39.6 %)0.0914 (6.6 %)34 (55.7 %)23 (37.7 %)0.785Age (years) \<703 (4.2 %)39 (54.9 %)29 (40.9 %)0.47516 (8.2 %)40 (54.8 %)27 (37 %)0.5932 ≥702 (11.8 %)9 (52.9 %)6 (35.3 %)1.4881 (5.6 %)8 (44.4 %)9 (50 %)1.045Smoking status Current smokers4 (6.2 %)35 (54.7 %)25 (39.1 %)0.53695 (7.7 %)35 (53.8 %)25 (38.5 %)0.0505 Ex-smokers--10 (55.6 %)8 (44.4 %)3.126--10 (50 %)10 (50 %)9.464 Non-smokers1 (20 %)2 (40 %)2 (40 %)2 (40 %)2 (40 %)1 (20 %)Histopathological diagnosis Adenocarcinoma3 (6.8 %)22 (50 %)19 (43.2 %)0.66484 (8.7 %)26 (56.5 %)16 (34.8 %)0.8393 Squamous cell carcinoma--8 (57.1 %)6 (42.9 %)4.088--7 (50 %)7 (50 %)2.752 Large cell carcinoma1 (6.7 %)11 (73.3 %)3 (20 %)2 (12.5 %)7 (43.75 %)7 (43.75 %) NOS NSCLC1 (6.6 %)7 (46.7 %)7 (46.7 %)1 (6.7 %)8 (53.3 %)6 (40 %)Stage of disease IIIB3 (11.1 %)16 (59.3 %)8 (29.6 %)0.20322 (7.1 %)15 (53.6 %)11 (39.3 %)0.9891 IV2 (3.3 %)32 (52.4 %)27 (44.3 %)3.1875 (7.9 %)33 (52.4 %)25 (39.7 %)0.022Performance status PS = 01 (8.3 %)7 (58.3 %)4 (33.3 %)0.83811 (9.1 %)5 (45.45 %)5 (45.45 %)0.9889 PS ≥ 14 (5.3 %)41 (53.9 %)31 (40.8 %)0.3536 (9.2 %)28 (43.1 %)31 (47.7 %)0.022

Response to chemotherapy {#Sec5}
------------------------

There were no cases of complete remission (CR) as a result of first-line chemotherapy with platinum compounds and gemcitabine. Control of the disease was observed in 54.9 % of patients, of which partial remission (PR) and stable disease (SD) occurred, respectively, in 17.6 and 37.3 % of patients. Disease progression (PD) was observed in 45.1 % of patients. Patients with squamous cell carcinoma or those who develop anemia before chemotherapy had a significantly lower chance of disease control (*p* = 0.0392, OR = 0.27; *p* = 0.0189, OR = 0.33, respectively) when compared to other patients. Moreover, in patients with poor performance status (PS = 1) the risk of PD (*p* = 0.0495, OR = 4.87) was higher. There were no statistically significant differences in response according to other demographic and clinical factors. Both SNPs: −37C\>A and −524C\>T of *RRM1* did not affect significantly the possibility of responses to treatment. In logistic regression analysis (including: sex, age, histopathological diagnosis, stage of disease, PS and SNPs of *RRM1*; overall fit of the model: *χ*^2^ = 22.45, *p* = 0.0021) only PS (*p* = 0.0002, OR = 0.0849 95 % CI 0.02--0.31) had an independent influence on ORR. Effect of SNPs of *RRM1* was insignificant, however, the CC genotype (−37C\>A) show a trend towards significance (*p* = 0.0655).

Progression-free survival {#Sec6}
-------------------------

The median PFS of whole group of patients was 4 months. In patients who were diagnosed with adenocarcinoma or non-squamous cell carcinoma compared to squamous cell carcinoma patients a significantly lower risk of shortening PFS was noticed (respectively, 6 vs 3 months, *p* = 0.0456, HR = 0.61, 95 % CI 0.37--0.99 and 4.5 vs 2 months, *p* = 0.0140, HR = 0.34, 95 % CI 0.14--0.80). In patients with IIIB stage of NSCLC and patients without anemia compared to other patients, the risk of shortening of PFS was significantly lower (respectively, 7 vs 3, *p* = 0.0094, HR = 0.52, 95 % CI 0.32--0.85; 6.5 vs 3 months, *p* = 0.0154, HR = 0.54, 95 % CI 0.33--0.89). Other factors did not affect PFS significantly.

Carriers of the C allele of the *RRM1* (−37C\>A) showed a significant increase in the risk of PFS shortening in comparison to patients with the AA genotype (3.5 vs 10.5 months, *p* = 0.0437; HR = 2.17, 95 % CI 1.02--4.62, Fig. [2](#Fig2){ref-type="fig"}). Similarly, the presence of the T allele of *RRM1* (−524C\>T) was associated with a significant risk of shortening of PFS when confronted with the CC genotype carriers (3.5 vs 10.5 months, *p* = 0.0437; HR = 2.12, 95 % CI 1.06--4.27, Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The probability of progression-free survival change depending on *RRM1* genotype (−37C\>A)Fig. 3The probability of progression-free survival change depending on *RRM1* genotype (−524C\>T)

In a Cox multivariate logistic regression analysis, poor (PS = 1) performance status (*p* = 0.0117, HR = 2.75, 95 % CI 1.26--6.02) and anemia prior to treatment (*p* = 0.0128, HR = 2.67, 95 % CI 1.24--5.74) were independently responsible for shortening of PFS in patients treated with chemotherapy using platinum compounds and gemcitabine (overall fit of the model: *p* = 0.0271, *χ*^2^ = 24.466) (Table [3](#Tab3){ref-type="table"}).Table 3Effect of demographic, clinical and genetic factors on overall response rates, progression-free survival and overall survival in the study groupVariablePD 41 (45.1 %)SD, PR 50 (54.9 %)*p*, OR 95 % CIMedian PFS (mo.)*p, χ* ^2^HR 95 % CIMedian OS (mo.)*p, χ* ^2^HR (95 % CI)Sex Male31 (50.8 %)30 (49.2 %)0.1179, 0.483940.86530.9560130.72801.1177 Female10 (33.3 %)20 (66.7 %)0.1948--1.202260.02880.5684--1.6079110.12100.5971--2.0923Age (years) ≤7034 (46.6 %)39 (53.4 %)0.5581, 0.72993.560.63440.871911.50.78120.9061 \>707 (38.9 %)11 (61.1 %)0.2546--2.09290.22620.4956--1.533916.50.07720.4519--1.8169Smoking status Smokers39 (45.9 %)46 (54.1 %)0.7978, 0.786347.50.53470.744111.50.88510.9187 Non-smokers2 (40 %)3 (60 %)0.125--4.94810.38540.2926--1.892118.50.02090.2909-2.9012Histopathological diagnosis Adenocarcinoma18 (40 %)27 (60 %)--60.1356--120.6073-- Squamous cell carcinoma10 (71.4 %)4 (28.6 %)25.55176.51.8352 Large cell carcinoma8 (47.1 %)9 (52.9 %)413 NOS NSCLC5 (33.3 %)10 (66.7 %)3.59.5 Adenocarcinoma18 (39.1 %)28 (60.9 %)0.2520, 1.62636[0.0456]{.ul}0.6074120.40940.7802 Other23 (51.1 %)22 (48.9 %)0.7077--3.73713[3.9962]{.ul}0.3725--0.990311.50.68050.4326--1.4071 Squamous cell carcinoma10 (71.4 %)4 (28.6 %)[0.0392, 0.2696]{.ul}2[0.0140]{.ul}0.33996.50.18070.5301 Non-squamous cell carcinoma31 (40.3 %)46 (59.7 %)[0.0776--0.9369]{.ul}4.5[6.0383]{.ul}0.1437--0.8038121.79160.2093--1.3427 Large cell carcinoma8 (50 %)8 (50 %)0.6619, 0.78573.7540.49720.8030130.99211.0036 Other33 (44 %)42 (56 %)0.2666--2,31570.46080.4263--1.512811.50.00010.4928--2.0439Stage of disease IIIB10 (35.7 %)18 (64.3 %)0.2348, 1.74387[0.0094]{.ul}0.5212180.07010.5687 IV31 (49.2 %)32 (50.8 %)0.6968--4.36413[6.7519]{.ul}0.3188--0.8520103.28000.3088--1.0475Performance status PS = 02 (16.7 %)10 (83.3 %)[0.0495, 4.8750]{.ul}7.50.26940.7024210.07000.5124 PS ≥139 (49.4 %)40 (50.6 %)[1.0031--23.691]{.ul}3.51.21970.3752--1.3148113.28310.2485--1.0562Weight loss before CTH Yes17 (43.6 %)22 (56.4 %)0.9567, 1.024560.70400.905818[0.0376]{.ul}0.4632 No19 (44.2 %)24 (55.8 %)0.4278--2.453830.14430.5436--1.50927.5[4.3237]{.ul}0.2242--0.9568Anemia before CTH Yes32 (54.2 %)27 (45.8%)[0.0189, 0.3302]{.ul}3[0.0154]{.ul}0.5430110.38440.7685 No9 (28.1 %)23 (71.9 %)[0.1309--0.8329]{.ul}6.5[5.8656]{.ul}0.3313--0.8901130.75650.4246--1.3910Side effect after CTH Yes------4.50.30080.7515120.34350.7231 No41.07060.4374--1.2911210.89740.3697--1.4142Subsequent lines of treatment Yes------50.71570.913116.5[0.0305]{.ul}0.5011 No30.13260.5596--1.48978[4.6802]{.ul}0.2680--0.9371Family history of cancer (any malignant) Yes6 (33.3 %)12 (66.7 %)0.3367, 1.75003.50.83890.93497.50.43200.7412 No21 (46.7 %)24 (53.3 %)0.5588--5.481030.04130.4887--1.7885)11.50.61750.3511--1.5645*RRM1* (−37C\>A) AA--5 (100 %)--10.50.0986--18.50.0677-- AC23 (47.9 %)25 (52.1 %)44.6330185.3846 CC15 (42.9 %)20 (57.1 %)3.59.5 AA--5 (100 %)0.1352, 9.307710.5[0.0437]{.ul}2.173618.50.85281.1004 AC or CC38 (45.7 %)45 (54.3 %)0.4986--173.753.5[4.0687]{.ul}1.0222--4.622011.50.03440.4006--3.0223 AC23 (47.9 %)25 (52.1 %)0.3270, 0.6522440.78401.070718[0.0351]{.ul}1.9088 AA or CC15 (37.5 %)25 (62.5 %)0.2775--1.5330.07510.6569--1.745211[4.4381]{.ul}1.0460--3.4833 CC15 (42.9 %)20 (57.1 %)0.9601, 1.02223.50.09281.56139.5[0.0193]{.ul}2.1346 AA or AC23 (43.3 %)30 (56.7 %)0.4316--2.42085.52.82490.9286--2.625118[5.4786]{.ul}1.1312--4.0281*RRM1* (−524C\>T) CC1 (14.3 %)6 (85.7 %)--10.50.0923--18.50.4129-- CT24 (50 %)24 (50 %)3.54.766411.51.7691 TT16 (44.4 %)20 (55.6 %)3.510 CC1 (14.3 %)6 (85.7 %)0.1237, 5.454510.5[0.0343]{.ul}2.124918.50.59831.2875 CT or TT40 (47.6 %)44 (52.4 %)0.6291--47.2933.5[4.4805]{.ul}1.0574--4.2700110.27760.5029--3.2959 CT24 (50 %)24 (50 %)0.3174, 0.65383.50.91410.974011.50.33180.7505 CC or TT17 (39.5 %)26 (60.5 %)0.2843--1.50460.01160.6035--1.5720110.94170.4204--1.3399 TT25 (45.4 %)30 (54.6 %)0.9246, 0.96003.50.09831.5342100.18071.5055 CT or CC16 (44.4 %)20 (55.6 %)0.4124--2.234742.73360.9237--2.5484131.79200.8270--2.7404

Overall survival {#Sec7}
----------------

The median OS in the study population was 12 months. The median OS was significantly longer in patients without weight loss prior to chemotherapy compared to other patients (respectively, 18 vs 7.5 months, *p* = 0.0376; HR = 0.46, 95 % CI 0.22--0.96). Patients who were treated with subsequent lines of treatment showed significantly longer OS than patients who received only one line of treatment (16.5 vs 8 months, *p* = 0.0305; HR = 0.50, 95 % CI 0.27--0.94). However, when compared separately none of second-line scheme has not improve survival significantly (ERL vs other 11.5 vs 10 mo.; *p* = 0.4270, HR = 1.37, 95 % CI 0.63--2.99; PEM vs other 13 vs 11 mo.; *p* = 0.1813, HR = 1.51, 95 % CI 0.82--2.76; DCX vs other 16.5 vs 12 mo.; *p* = 0.3365, HR = 0.67, 95 % CI 0.29--1.52). There was no statistically significant effect of other factors on the OS.

The CC genotype carriers of *RRM1* (−37C\>A) showed a significant increase in the risk of shortening of OS compared to patients with AA or AC genotypes (9.5 vs 18 months, *p* = 0.0193; HR = 2.13, 95 % CI 1.13--4.03, Fig. [4](#Fig4){ref-type="fig"}). None of the SNP −524C\>T variants did significantly affect the length of OS in the study group (e.g. CC vs CT or TT, 18.5 vs 11 months, *p* = 0.5983, HR = 1.29, 95 % CI 0.50--3.30; Fig. [5](#Fig5){ref-type="fig"}).Fig. 4The probability of overall survival change depending on *RRM1* genotype (−37C\>A)Fig. 5The probability of overall survival change depending on *RRM1* genotype (−524C\>T)

Poor performance status (PS = 1, *p* = 0.0053, HR = 5.81, 95 % CI 1.70--19.93) and lack of subsequent lines of treatment (*p* = 0.0246, HR = 2.58, 95 % CI 1.15--7.53) were only factors that shorten OS in a Cox multivariate logistic regression analysis (overall fit of the model *χ*^2^ = 27.73, *p* = 0.0233).

Discussion {#Sec8}
==========

Despite progress in medicine, that has been made in recent years, there are still lack of predictive factors, which would allow qualify NSCLC patients to appropriate chemotherapy regimen. The current criteria of patients' selection to cytostatic-based therapy are primarily performance status, treatment toxicity and clinician's experience; however, it seems to be insufficient. In addition, most of the currently available chemotherapy regimens, regardless of the line of treatment, are characterized by significant differences in the effectiveness in various patients. This is another evidence that key to prediction of occurrence of resistance to cytostatics may be stored in genetic information \[[@CR10]--[@CR12], [@CR18], [@CR19]\].

Reliable evaluation of mRNA or protein expression requires access to the tumor tissue Tumor tissue in an advanced stages of NSCLC is difficult or, sometimes, impossible to obtain. Changes in the structure, function, stability, folding or expression of proteins may be caused by occurrence of specific SNPs in encoding or non-coding sequences (especially located in promoter region) of genes. Moreover, the analysis of SNPs may be carried out in materials that are easy to obtain (e.g. DNA from peripheral blood leukocytes) and thus easier introduced into routine clinical practice. Consequently, many studies (unfortunately mainly retrospective) assessed the effect of the individual polymorphic variants of different genes on the effectiveness of various treatment regimens.

There is lack of meta-analysis evaluating the impact of any *RRM1* SNPs on response to treatment, PFS or OS in patients with NSCLC treated with gemcitabine. Among the eight original papers investigating relationship of SNPs (−37C\>A and/or −524C\>T) with response to treatment, four of them concerned Asian patients. Feng et al. analyzed both mentioned SNPs (genotypes) independently and in combination in 214 patients treated with different schemes chemotherapy based on platinum. Kim et al. evaluated allelotype of two mentioned SNPs in 97 patients received chemotherapy based on gemcitabine. Lin et al. estimated only relationship between −37C\>A polymorphism and effectiveness of chemotherapy regimens containing gemcitabine in 40 NSCLC patients. Dong et al. assessed SNPs in 56 patients treated with chemotherapy based on gemcitabine \[[@CR16], [@CR17], [@CR20], [@CR21]\]. In studies concerning Caucasian population, analysis of −37C\>A SNP was presented by Isla et al. (62 patients received platinum compounds in combination with docetaxel), Vinolas et al. (94 patients treated with platinum compounds in combination with vinorelbine) and Mlak et al. (62 patients treated with platinum compounds in combination with gemcitabine). While, Ludovini et al. assessed −524C\>T SNPs in 168 patients received platinum-based chemotherapy \[[@CR22]--[@CR25]\].

Feng and co-workers did not demonstrate the association between the −37C\>A SNP and the response to chemotherapy. However, the statistically significant relationship between −524C\>T SNP of *RRM1* and response to treatment (*χ*^2^ = 6.179, *p* = 0.046) was proved \[[@CR16]\]. In contrast, Kim et al. reported a significantly higher response rate in patients with genotype AC/CT (−37C\>A/−524C\>T) in comparison to carriers of other combinations of *RRM1* allelotypes (65.5 vs 42.6 %, *p* = 0.039) \[[@CR18]\]. Lin et al. and Dong et al. have shown no significant differences in response to treatment depending on the *RRM1* genotype \[[@CR17], [@CR19]\]. Isla et al., Vinolas et al., Ludovini et al. demonstrated no correlation between the genotype of *RRM1* and response to the treatment \[[@CR23]--[@CR25]\].

The only evidence for association of −37A\>C polymorphism and response to gemcitabine-based chemotherapy was reported in our previous study. We indicated that AC genotype was significantly related with less frequent response to chemotherapy (*χ*^2^ = 5.47, *p* = 0.0193). It was probably caused by the influence of A allele (importance of AA genotype was impossible to assess due to small study group). In addition, this study showed a significant association between the presence of genotype AA or AC and early progression of the disease (*χ*^2^ = 3.61; *p* = 0.0573) \[[@CR22]\].

In the available literature six studies describe the relationship between SNPs of *RRM1* and the duration of the PFS (Dong et al., Mlak et al., Vinolas et al., Isla et al., Kim et al., Ludovini et al.) and OS (Ryu et al., Mlak et al., Vinolas et al., Isla et al., Kim et al., Ludovini et al.) in patients with NSCLC treated in the first-line with platinum and third generation drug scheme (usually gemcitabine) \[[@CR16], [@CR20], [@CR22]--[@CR26]\]. Dong et al. presented the positive study regarding the impact of *RRM1* SNPs on the length of PFS. Authors demonstrated significant differences in the PFS depending on −37C\>A SNP (23.3, 30.7, 24.7 weeks for Asian patients with CC, CA, AA genotype, respectively, *p* = 0.043) \[[@CR17]\]. Among the studies concerning Caucasian patients, only in our previous publication the presence of a significant effect of CC genotype (−37C\>A) on reduction of the risk of shortening both PFS (6 months for patients with CC genotype vs 2 months for others patients, HR = 0.51, 95 % CI 0.29--0.89, *p* = 0.0087) and OS (16.5 months for patients with CC and 8 months for patients CA or AA genotypes, HR = 0.47; 95 % CI 0.22--0.99, *p* = 0.0448) was demonstrated \[[@CR22]\]. Other studies revealed no significant association between polymorphic variants of *RRM1* (−37C\>A and/or −524C\>T) and the length of PFS and/or OS in patients with NSCLC treated with first-line chemotherapy.

Therefore, statistically significant relationship between −524C\>T SNP of *RRM1* and the PFS length (CC genotype was significantly associated with prolongation of PFS) in patients with advanced NSCLC who were treated first-line chemotherapy based on platinum compounds and gemcitabine was described for the first time in present study. We also verified the results of the impact of −37C\>A SNP on the PFS (AA genotype was significantly associated with PFS prolongation) and OS (CC genotype was significantly associated with OS shortening), described previously in smaller populations of NSCLC \[[@CR17], [@CR22]\]. The limitations of our research are retrospective character of analysis and heterogeneous study group.

Unfortunately, despite growing evidence suggesting that SNPs in genes encoding proteins involved in drug metabolism and DNA repair may help to explain the inter-individual variability of response or resistance to chemotherapy, most of available studies present conflicting results.

Differences between studies may be due to: (1) race differences (Asian vs Caucasian patients), which are reflected both in the incidence of SNPs and in phenotypic disparity; (2) NSCLC has many subtypes (characterized by, e.g.: differences in driver mutations occurrence and clinical course) thus in most studies different proportion of each subtype may occur. Differences in course of treatment: in some studies; (3) part of patients received chemoradiation. In first-line regimens different platinum compound (cis- or carboplatin) may be used; (4) In subsequent lines most patients are treated with multiple drugs, including: pemetrexed, docetaxel, and an TKI, as well as may undergo surgery, which significantly affects course of disease and survival.

Accordingly, it is crucial to conduct a large randomized prospective studies taking into account the respective proportions of race, subtypes of NSCLC, as well as based on suitable standards and uniform regimens of treatment.

Conclusions {#Sec9}
===========

The presence of rare genotypes: AA (−37C\>A) and CC (−524C\>T) of *RRM1* promoter are favorable predictors associated with prolongation of PFS in NSCLC patients treated with first-line chemotherapy with platinum compounds and gemcitabine. Moreover, occurrence of CC genotype (−37C\>A) is unfavorable predictor of OS shortening. Evaluation of selected SNPs of *RRM1* may in the future, become a useful tool in the qualification of patients with NSCLC to the appropriate chemotherapy regimen. However, our results should be previously confirmed in sufficiently large and prospective studies.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Committee Ethics and Research at the Medical University of Lublin (no. consent: KE-0254/142/2010). This article does not contain any studies with animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Conflict of interest {#FPar1}
====================

The authors declare no conflicts of interest.
